BRAF and melanoma: Pazopanib, as well as being a kinase inhibitor, is also a potent inhibitor of chaperone ATPase activities and recently it was shown that [pazopanib + AR42] treatment of melanoma cells reduced the abilities of HSP90 and HSP70 to chaperone RAF-1 and B-RAF [7, 8].